Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $16.57 Consensus Target Price from Analysts

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) have been given an average recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $16.5714.

A number of analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, January 9th. Wells Fargo & Company upgraded Relay Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $6.00 to $13.00 in a report on Friday, December 12th. Finally, Oppenheimer raised Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price for the company in a report on Monday, January 26th.

Relay Therapeutics Stock Up 2.6%

Shares of NASDAQ RLAY opened at $9.16 on Friday. Relay Therapeutics has a 12-month low of $1.77 and a 12-month high of $9.54. The company’s fifty day simple moving average is $8.20 and its 200 day simple moving average is $6.44. The firm has a market cap of $1.59 billion, a PE ratio of -5.23 and a beta of 1.59.

Insider Activity

In related news, insider Donald A. Bergstrom sold 18,895 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total value of $143,979.90. Following the transaction, the insider directly owned 422,733 shares of the company’s stock, valued at approximately $3,221,225.46. The trade was a 4.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Thomas Catinazzo sold 13,820 shares of the firm’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40. Following the completion of the transaction, the chief financial officer directly owned 250,996 shares of the company’s stock, valued at approximately $1,912,589.52. This trade represents a 5.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 93,302 shares of company stock worth $724,355. 4.32% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Relay Therapeutics by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock worth $71,000 after acquiring an additional 1,757 shares in the last quarter. Abel Hall LLC raised its stake in shares of Relay Therapeutics by 16.2% during the 4th quarter. Abel Hall LLC now owns 12,984 shares of the company’s stock worth $110,000 after purchasing an additional 1,809 shares in the last quarter. Cresset Asset Management LLC grew its stake in shares of Relay Therapeutics by 5.0% in the 3rd quarter. Cresset Asset Management LLC now owns 38,932 shares of the company’s stock valued at $203,000 after buying an additional 1,848 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its position in Relay Therapeutics by 8.1% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 27,871 shares of the company’s stock worth $145,000 after acquiring an additional 2,079 shares in the last quarter. Finally, Prelude Capital Management LLC lifted its stake in shares of Relay Therapeutics by 18.7% in the 3rd quarter. Prelude Capital Management LLC now owns 19,700 shares of the company’s stock valued at $103,000 after purchasing an additional 3,100 shares during the last quarter. 96.98% of the stock is currently owned by hedge funds and other institutional investors.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.